H. Lundbeck A/S/€HLUNB
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About H. Lundbeck A/S
H. Lundbeck A/S is a Danish pharmaceutical company focused on the research, development, production, and marketing of pharmaceuticals for the treatment of brain disorders. Headquartered in Copenhagen, Denmark, Lundbeck's core business includes a portfolio of products addressing conditions such as depression, anxiety, schizophrenia, Alzheimer's disease, and Parkinson's disease. The company has a significant presence in the neuropharmaceuticals industry, striving to deliver innovative solutions to patients with unmet medical needs. Lundbeck operates internationally, distributing its products across multiple markets, supported by its strategic positioning in research and development. Unique competitive strengths include its dedicated focus on central nervous system disorders and ongoing investments in innovative therapies.
Ticker
€HLUNB
Sector
Primary listing
XGAT
Employees
5,700
Headquarters
Valby, Denmark
Website
H. Lundbeck A/S Metrics
BasicAdvanced
€5.5B
11.29
€0.51
0.38
€0.13
2.19%
Price and volume
Market cap
€5.5B
Beta
0.38
52-week high
€6.43
52-week low
€3.64
Average daily volume
21K
Dividend rate
€0.13
Financial strength
Current ratio
1.467
Quick ratio
0.998
Long term debt to equity
49.028
Total debt to equity
49.33
Dividend payout ratio (TTM)
24.76%
Interest coverage (TTM)
12.53%
Profitability
EBITDA (TTM)
1,048.414
Gross margin (TTM)
83.01%
Net profit margin (TTM)
15.82%
Operating margin (TTM)
25.50%
Effective tax rate (TTM)
20.76%
Revenue per employee (TTM)
€564,970
Management effectiveness
Return on assets (TTM)
8.28%
Return on equity (TTM)
15.55%
Valuation
Price to earnings (TTM)
11.291
Price to revenue (TTM)
1.786
Price to book
1.64
Price to tangible book (TTM)
-4
Price to free cash flow (TTM)
15.48
Free cash flow yield (TTM)
6.46%
Free cash flow per share (TTM)
0.375
Dividend yield (TTM)
2.19%
Forward dividend yield
2.19%
Growth
Revenue change (TTM)
12.30%
Earnings per share change (TTM)
41.73%
3-year revenue growth (CAGR)
10.97%
10-year revenue growth (CAGR)
5.49%
3-year earnings per share growth (CAGR)
33.49%
10-year earnings per share growth (CAGR)
-4.35%
3-year dividend per share growth (CAGR)
33.42%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for H. Lundbeck A/S stock?
H. Lundbeck A/S (HLUNB) has a market cap of €5.5B as of December 14, 2025.
What is the P/E ratio for H. Lundbeck A/S stock?
The price to earnings (P/E) ratio for H. Lundbeck A/S (HLUNB) stock is 11.29 as of December 14, 2025.
Does H. Lundbeck A/S stock pay dividends?
Yes, the H. Lundbeck A/S (HLUNB) stock pays dividends to shareholders. As of December 14, 2025, the dividend rate is €0.12727 and the yield is 2.19%. H. Lundbeck A/S has a payout ratio of 24.76% on a trailing twelve-month basis.
When is the next H. Lundbeck A/S dividend payment date?
The next H. Lundbeck A/S (HLUNB) dividend payment date is unconfirmed.
What is the beta indicator for H. Lundbeck A/S?
H. Lundbeck A/S (HLUNB) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.